Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
There is obviously positivity from LTH as they know what is coming and don’t really care when! This will fluctuate as the MM’s know it is a safe bet. They can drive it up and down easily and if they are in when news arrive, they know they will multibag! Win win! I also find it irritating when MM’s manage to get in the 5’s But, I have averaged down over the last year and I am happy with my holding, even though it is higher than the 5’s.... Just! Forget the peaks and troughs if you can and wait for the end game:)
You just be special
Barwickman you bring little to the table except your miserable comments so do one if you aren't happy with other posters.
I value those that at least make some effort in giving relevant information.
no disrespect Barwickman; but coming from the king of pointless posters, that's pretty rich. Who made you the msg board police? Everyone here is entitled to their own views, including you. All you seem to be doing the last few days is slating others for expressing theirs.
Thanks Yorkshireboy. Informative and that is what is great about this company. Truly, life-changing drugs that are quick to clinic, and commercially significant. That's why they are in advanced talks and why when the deal happens this will fly.
Of of barwick... shorter shorter ... lol
Continued
Although, if its lack of confidence due to the fluctuating SP, I suggest the following: - ‘Things Can Only Get Better’
https://www.youtube.com/watch?v=7W3yz6abJkU
Please DYOR and enjoy the sing along.
Good Luck
I just thought I would remind investors why the appointment of Dr Muhunthan Thillai to Nuformix's Scientific Advisory Board was a prodigious achievement. At the time NFX stated: - ‘The appointment reflects progress made with Nuformix's NXP002 programme as a treatment for Idiopathic Lung Fibrosis (IPF) as it finalises its clinical development plans.
Muhunthan stated: - "It is a pleasure to be joining the Nuformix team at this point. The data generated to date in human IPF tissue slices versus current therapies demonstrates real promise in preventing disease progression and extending life free from side effects. Current therapies lack meaningful efficacy and their side effects can be so severe that some patients elect to stop treatment. Nuformix's approach offers the potential to move rapidly into clinic and allows us to explore other unmet needs in interstitial lung disease together."
Dan stated: - ‘His in-depth understanding of patients' needs, and the short-comings of existing therapies will enable Nuformix to identify how our NXP002 programme can offer greatest benefit for his patients. Muhunthan has already contributed to numerous IPF clinical studies and is currently developing new technologies and novel imaging biomarkers that improve assessment of disease progression. On top of this, he is highly respected by his peers and well connected with the major academic and pharmaceutical players in IPF.’
RNS Number: 4774L Nuformix PLC 06 September 2019.
In addition to Mars1 excellent post, I just thought I’d add the following morsel: -
Dr Muhunthan Thillai is one of 2 Directors of ‘Qureight Ltd’ which was founded in 2018 by 2 Cambridge doctors. Their platform enables analysis of images and data from multiple sources to better model diseases and assist with clinical trial endpoints.
Recently, their company has made it onto the respected 2020 Confinitive: - #21toWatch, shortlist.
https://www.cofinitive.com/21towatch/
Out of hundreds of entries received, 246 qualified candidates made it onto a longlist, which has now been whittled down to a shortlist of 56, featuring a dynamic mix of people, companies and ‘things’. https://www.cambridgeindependent.co.uk/business/21towatch-shortlist-of-people-companies-and-things-revealed-9099373/
The #21toWatch list will be divided into innovative and trailblazing people, companies and ‘things’ that are en route to being industry game-changers locally, nationally and globally.
https://www.cofinitive.com/21towatch/companies/
Since being invested, I have always had the greatest respect for Dan and the organisation and the prospective rewards it will deliver. Not only to investors but science/pharmaceutical development and its ultimate altruistic/therapeutic benefits. Therefore, have no intention of diluting my holding, however, I have no problem if fellow investors wish to do so, hey ho it’s their choice and they must have their reasons.
investor
what a load nonsense.
Rise last week was on the back of Japan news expectation.
Priced at the moment reflects that fact that China deal has completely fallen through !
Hopefully Japan news shortly, great posts by Mars1!
Muhunthan Thillai appears to be the real deal and some of the things he is involved in are amazing!
All makes complete sense.
Investor1111 - there is no absolute that it is the ex-ceo - there has been a seller for a while.
Dan has to release news as soon as its apparent
I agree there are background sellers and the share will not rerate until we get positive news and the big investors move in. This is when the market will take the sells without hammering the price
Professor Kaminski from Yale has tweeted
Naftali Kaminski
@KaminskiMed
·
Feb 17
Did small airway disease just become a feature of IPF? Read this superb editorial that integrates the two recent papers on loss of small airways in IPF
Afraid if there's material news to be released it has to be released - you can't release it when it suits you.
Its absolutely clear to see what is happening here, cpi and ex ceo are selling, sp went down to 4,5,6 and the selling stopped as a result the sp went up last week, the selling has begun, these sellers want a decent return, they dont want to sell below 6p, it will take months for the sellers to clear and it the meantime any news that arrives the sellers will make sure they put all the stops on a rerate (new floor), if i was dan i would not release any news until the sellers had finished even if it means waiting 12 months that way the sp would be free to rise
Also forgot to mention this is ground breaking research airway measurement has never been done or results proved before.
Should have said no one else has an inhaling therapy
That report below is now public information from leaders in their field and will be read by all the leading pharma companies in IPF. No one has an inhaling therapy.
Now it is clear why inhaled therapy is the best route for NXP002 from the best brains in IPF
Article by many including Muhunthan Thillai
On IPF and airways
https://openres.ersjournals.com/content/6/1/00290-2019